Clinical Physiology of Circulation

ISSN 1814-6910 (Print)
ISSN 2410-9134 (Online)

 

Chief Editor

Leo A. Bockeria, MD, PhD, DSc, Professor, Academician of Russian Academy of Sciences, President of Bakoulev National Medical Research Center for Cardiovascular Surgery


Issue's catalogue ➤ КФК. 2025; 22 (1): 1-114 ➤ PCSK9-направленная терапия: достигнутый уровень и перспективы (систематический обзор исследований 2023−2025 гг.)

PCSK9-directed therapy: current status and prospects (2023−2025 research хsystematic review)

Authors: Kanorsky S.G., Polischuk L.V., Pokrovsky V.M.

Company:
Kuban State Medical University, Krasnodar, Russian Federation

E-mail: Сведения доступны для зарегистрированных пользователей.

DOI: https://doi.org/10.24022/1814-6910-2025-22-1-21-32

UDC: 615.214.32

Link: Clinical Physiology of Blood Circulaiton. 2025; 22 (1): 21-32

Quote as: Kanorsky S.G., Polischuk L.V., Pokrovsky V.M. PCSK9-directed therapy: current level and prospects (2023−2025 research systematic review). Clinical Physiology of Circulation. 2025; 22 (1): 21–32 (in Russ.). DOI: 10.24022/1814-6910-2025-22-1-21-32

Keywords:  PCSK9-inhibitors inclisiran evolocumab alirocumab MK-0616 recaticimab ongericimab lerodalcibep

Received / Accepted:  27.01.2025 / 14.02.2025

Full text:
Subscribe 🔒

Abstract

Pharmacological inhibition of proprotein convertase subtilisn/kexin type 9 (PCSK9) is a state-of-the-art mechanism to reduce low-density lipoprotein cholesterol and the risk of cardiovascular complications. The systematic review analyzing outcomes from randomized controlled trials and post hoc data published in 2023−2025 on PCSK9 inhibition therapies is presented. The purpose of the systematic review is to assess the current data on the safety and efficacy of used PCSK9 inhibitors, as well as to highlight trends in the development of new strategies for PCSK9 function inhibiting. The systematic search was conducted in the PubMed database (combining data from the MEDLINE, PreMEDLINE, NLM systems) using the descriptor “PCSK9” in the search order, according to the thesaurus of the MeSH (Medical Subject Headings), as well as the corresponding time interval and the randomized controlled trial criterion. As a result of the search, 38 publications were found. The methodological quality of the studies was assessed according to the criteria of the Cochrane Community. 38 trials are included in the analysis. The 2023−2025 studies confirmed that long- term inhibition of PCSK9 by monoclonal antibodies, small interfering RNA inclisiran treatment are safe and provide a reduction in cardiovascular risks. At the same time, new strategies that are being developed can expand the therapeutic possibilities in this area.

References

  1. Trybhat T.A., Shut S.V., Borisova Z.O., Sakevych V.D., Goncharova O.O. Some characteristics of the course of coronary heart disease with a comorbid pathology. Med. Ecol. Probl. 2020; 24 (1–2): 8–11. DOI: 10.31718/mep.2020.24.1-2.02
  2. Голухова Е.З. Отчет о научной и лечебной работе Национального медицинского исследовательского центра сердечно- сосудистой хирургии им. А.Н. Бакулева Минздрава России за 2023 год и перспективы развития. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2024; 25 (Спецвыпуск): 5–141. DOI: 10.24022/1810-0694-2024-25S
  3. Zheng W., Huang X., Wang X., Suo M., Yan Y., Gong W., Nie S. Impact of multimorbidity patterns on outcomes and treatment in patients with coronary artery disease. Eur. Heart J. Open. 2024; 4 (2): 1–8. DOI: 10.1093/ehjopen/oeae009
  4. Бузиашвили Ю.И., Асымбекова Э.У., Тугеева Э.Ф., Ахмедов Д.Р., Акилджонов Ф.Р. Мультимодальный подход к ранней верификации кардиотоксичности, ассоциированной с химиотерапией. Сердечно-сосудистые заболевания. Бюллетень НЦССХ им. А.Н. Бакулева РАМН. 2025; 26 (1): 5–12. DOI: 10.24022/1810-0694-2025-26-1-5-12
  5. Forman D.E., Maurer M.S., Boyd C., Brindis R., Salive M.E., Horne F.M., Rich M.W. Multimorbidity in older adults with cardiovascular disease. J. Am. Coll. Cardiol. 2018; 71 (19): 2149–2161. DOI: 10.1016/j.jacc.2018.03.022
  6. Mamalyga M.L. Contemporary problems of cardiovascular disorders at diabetes mellitus. Int. J. Diabetes Endocrinol. 2016; 1 (1): 1–7. DOI: 10.11648/j.ijde.20160101.11
  7. Guzik T.J., Touyz R.M. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017; 70 (4): 660–667. DOI: 10.1161/HYPERTENSIONAHA.117.07802
  8. Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J., Ziaeian B. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2019; 74 (10): e177–e232. DOI: 10.1016/j.jacc.2019.03.010
  9. Low Wang C.C., Hess C.N., Hiatt W.R., Goldfine A.B. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation. 2021; 133 (24): 2459–2502. DOI: 10.1161/CIRCULATIONAHA.116.022194
  10. Libby P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 2006; 83 (2): 456S–460S. DOI: 10.1093/ajcn/83.2.456S
  11. Jia G., Hill M.A., Sowers J.R. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ. Res. 2018; 122 (4): 624–638. DOI: 10.1161/CIRCRESAHA.117.311586
  12. Ginsberg H.N., Packard C.J., Chapman M.J., Borén J., Aguilar-Salinas C.A., Averna M., Tokgözoğlu L. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies – a consensus statement from the European Atherosclerosis Society. Eur. Heart J. 2021; 42 (47): 4791–4806. DOI: 10.1093/eurheartj/ehab551
  13. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473 (7347): 317–325. DOI: 10.1038/nature10146
  14. Tousoulis D., Oikonomou E., Economou E.K., Crea F., Kaski J.C. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur. Heart J. 2016; 37 (22): 1723–1732. DOI: 10.1093/eurheartj/ehv759
  15. Мамалыга М.Л. Сахарный диабет и его роль в формировании сердечно-сосудистых нарушений. М.: Прометей; 2016.
  16. Seferović P.M., Petrie M.C., Filippatos G.S., Anker S.D., Rosano G., Bauersachs J., Coats A.J. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2018; 20(5): 853–872. DOI: 10.1002/ejhf.1170
  17. Sarnak M.J., Amann K., Bangalore S., Cavalcante J.L., Charytan D.M., Craig J.C. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019; 74 (14): 1823–1838. DOI: 10.1016/j.jacc.2019.08.1017
  18. Lanzer P., Boehm M., Sorribas V., Thiriet M., Janzen J., Zeller T. Medial vascular calcification revisited: review and perspectives. Eur. Heart J. 2014; 35 (23): 1515–1525. DOI: 10.1093/eurheartj/ehu163
  19. Mullens W., Cotter G., Metra M., Milo-Cotter O., Dittrich H.C., Gheorghiade M. Fluid overload in acute heart failure – re-distribution and other mechanisms beyond fluid accumulation. Eur. J. Heart Fail. 2008; 10 (2): 165–169. DOI: 10.1016/j.ejheart.2008.01.007
  20. Xie X., Liu Y., Perkovic V., Li X., Ninomiya T., Hou W., Wang H. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am. J. Kidney Dis. 2016; 67 (5): 728–741. DOI: 10.1053/j.ajkd.2015.10.011
  21. Tanaka H., Komaba H., Koizumi M., Kakuta T., Fukagawa M. Role of uremic toxins and oxidative stress in the development of chronic kidney disease–mineral and bone disorder. J. Ren. Nutr. 2012; 22 (1): 98–101. DOI: 10.1053/j.jrn.2011.10.031
  22. Rangaswami J., Bhalla V., Blair J.E., Chang T.I., Costa S., Lentine K.L. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019; 139 (16): 840–878. DOI: 10.1161/CIR.0000000000000664
  23. Portolés J., Martín L., Broseta J.J., Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front. Med. 2021; 8: 642296. DOI: 10.3389/fmed.2021.642296
  24. Kent B.D., Mitchell P.D., McNicholas W.T. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int. J. Chron. Obstruct. Pulmon. Dis. 2011; 6: 199–208. DOI: 10.2147/COPD.S10611
  25. Tariq S., Ismail D., Thapa M., Goriparthi L., Pradeep R., Khalid K., Jean-Charles G. Chronic obstructive pulmonary disease and its effect on red blood cell indices. Cureus. 2023; 15 (3): e36100. DOI: 10.7759/cureus.36100
  26. Seeger W., Adir Y., Barberà J.A., Champion H., Coghlan J.G., Cottin V., Vachiery J.L. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62 (25): 109–116. DOI: 10.1016/j.jacc.2013.10.036
  27. Campo G., Pavasini R., Malagù M., Mascetti S., Biscaglia S., Ceconi C., Contoli M. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc. Drugs Ther. 2015; 29: 147–157. DOI: 10.1007/s10557-015-6581-x
  28. Roversi S., Roversi P., Spadafora G., Rossi R., Fabbri L.M. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 2014; 44 (1): 93–102. DOI: 10.1111/eci.12181
  29. Ortega-Paz L., Capodanno D., Angiolillo D.J. Canakinumab for secondary prevention of coronary artery disease. Future Cardiol. 2021; 17 (3): 427–442. DOI: 10.2217/fca-2020-0211
  30. Miklós Z., Horváth I. The role of oxidative stress and antioxidants in cardiovascular comorbidities in COPD. Antioxidants. 2023; 12(6): 1196. DOI: 10.3390/antiox12061196
  31. Daher A., Dreher M. The bidirectional relationship between chronic obstructive pulmonary disease and coronary artery disease. Herz. 2020; 45 (2): 110–117. DOI: 10.1007/s00059-020-04893-4
  32. Brown T.M., Pack Q.R., Aberegg E., Brewer L.C., Ford Y.R., Forman D.E., Thomas R.J. Core components of cardiac rehabilitation programs: 2024 update: a scientific statement from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2024; 150 (18): 328–347. DOI: 10.1161/CIR.0000000000001289
  33. Evdokimov V., Yushchuk E., Evdokimova A., Ivanova S., Sadulaeva I. Efficacy and safety of beta-blockers and prolonged bronchodilators in patients with heart failure with coronary artery disease and moderate to severe COPD. Eur. Heart J. 2020; 41 (2): 946–1156. DOI: 10.1093/ehjci/ehaa946.1156
  34. Jabbar A., Pingitore A., Pearce S.H., Zaman A., Iervasi G., Razvi S. Thyroid hormones and cardiovascular disease. Nat. Rev. Cardiol. 2017; 14 (1): 39–55. DOI: 10.1038/nrcardio.2016.174
  35. Gluvic Z.M., Zafirovic S.S., Obradovic M.M., Sudar-Milovanovic E.M., Rizzo M., Isenovic E.R. Hypothyroidism and risk of cardiovascular disease. Curr. Pharm. Des. 2022; 28 (25): 2065–2072. DOI: 10.2174/1381612828666220620160516
  36. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 2001; 344 (7): 501–509. DOI: 10.1056/NEJM200102153440707
  37. Ochs N., Auer R., Bauer D.C., Nanchen D., Gussekloo J., Cornuz J., Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann. Intern. Med. 2008; 148 (11): 832–845. DOI: 10.7326/0003-4819-148-11- 200806030-0022
  38. Udovcic M., Pena R.H., Patham B., Tabatabai L., Kansara A. Hypothyroidism and the heart. Methodist. DeBakey Cardiovasc. J. 2017; 13 (2): 55–59. DOI: 10.14797/mdcj-13-2-55
  39. Bano A., Chaker L., De Maat M.P., Atiq F., Kavousi M., Franco O.H., Peeters R.P. Thyroid function and cardiovascular disease: the mediating role of coagulation factors. J. Clin. Endocrinol. Metab. 2019; 104 (8): 3203–3212. DOI: 10.1210/jc.2019-00072
  40. Jean-Louis G., Zizi F., Clark L.T., Brown C.D., McFarlane S.I. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J. Clin. Sleep Med. 2008; 4 (3): 261–272. DOI: 10.5664/jcsm.27191
  41. Mooe T., Franklin K.A., Holmstrom K., Rabben T., Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am. J. Respir. Crit. Care Med. 2001; 164 (10): 1910–1913. DOI: 10.1164/rccm.2101072
  42. May A.M., Mehra R. Obstructive sleep apnea: role of intermittent hypoxia and inflammation. Semin. Respir. Crit. Care Med. 2014; 35 (5): 531–544. DOI: 10.1055/s-0034-1390023
  43. Jelic S., Lederer D.J., Adams T., Padeletti M., Colombo P.C., Factor P., Le Jemtel T.H. Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea. Vasc. Health Risk Manag. 2009; 5: 909–920. DOI: 10.2147/VHRM.S8123
  44. Punjabi N.M., Sorkin J.D., Katzel L.I., Goldberg A.P., Schwartz A.R., Smith P.L. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am. J. Respir. Crit. Care Med. 2002; 165 (5): 677–682. DOI: 10.1164/rccm.2104087
  45. Голухова Е.З., Магомедова Н.М. Слип-апноэ и сердечно-сосудистые риски. Креативная кардиология. 2016; 10 (3): 201–209. DOI: 10.15275/kreatkard.2016.03.03
  46. Guardiola J.J., Matheson P.J., Clavijo L.C., Wilson M.A., Fletcher E.C. Hypercoagulability in patients with obstructive sleep apnea. Sleep Med. 2001; 2 (6): 517–523. DOI: 10.1016/S1389-9457(01)00088-0
  47. Johansson P., Alehagen U., Ulander M., Svanborg E., Dahlström U., Broström A. Sleep disordered breathing in community dwelling elderly: associations with cardiovascular disease, impaired systolic function, and mortality after a six-year follow-up. Sleep Med. 2011; 12 (8): 748–753. DOI: 10.1016/j.sleep.2011.03.012
  48. Somers V.K., Amin R., Abraham W.T., Costa F., Culebras A., Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement. J. Am. Coll. Cardiol. 2008; 52 (8): 686–717. DOI: 10.1016/j.jacc.2008.05.002
  49. Celano C.M., Villegas A.C., Albanese A.M., Gaggin H.K., Huffman J.C. Depression and anxiety in heart failure: a review. Harv. Rev. Psychiatry. 2018; 26 (4): 175–184. DOI: 10.1097/HRP.0000000000000162
  50. Otte C., Gold S.M., Penninx B.W., Pariante C.M., Etkin A., Fava M., Schatzberg A.F. Major depressive disorder. Nat. Rev. Dis. Primers. 2016; 2: 16065. DOI: 10.1038/nrdp.2016.65
  51. Xu L., Zhai X., Shi D., Zhang Y. Depression and coronary heart disease: mechanisms, interventions, and treatments. Front. Psychiatry. 2024; 15: 1328048. DOI: 10.3389/fpsyt.2024.1328048
  52. Pariante C.M. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur. Neuropsychopharmacol. 2017; 27 (6): 554–559. DOI: 10.1016/j.euroneuro.2017.04.001
  53. Jesulola E., Micalos P., Baguley I.J. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model-are we there yet? Behav. Brain Res. 2018; 341: 79–90. DOI: 10.1016/j.bbr.2017.12.025
  54. Голухова Е.З., Асланиди И.П., Шурупова И.В., Шахова А.А., Румянцева М.Г., Трифонова Т.А., Суркова Н.А. Регионарные показатели перфузии и кровотока миокарда по данным количественной позитронно-эмиссионной томографии как индикаторы многососудистого поражения коронарного русла у больных ишемической болезнью сердца. Грудная и сердечно-сосудистая хирургия. 2023; 65 (2): 161–172. DOI: 10.24022/0236-2791-2023-65-2-161-172
  55. Голухова Е.З., Шурупова И.В., Дорофеев А.В., Рычина И.Е., Трифонова Т.А., Болдырева К.М. Характеристика глобального миокардиального кровотока и коронарного резерва по данным динамической стресс-компьютерной томографии у пациентов с ишемической болезнью сердца. Грудная и сердечно-сосудистая хирургия. 2024; 66 (5): 655–667. DOI: 10.24022/0236-2791-2024-66-5-655-667
  56. Köhler C.A., Freitas T.H., Stubbs B., Maes M., Solmi M., Veronese N., Carvalho A.F. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: Systematic review and meta-analysis. Mol. Neurobiol. 2018; 55 (5): 4195–4206. DOI: 10.1007/s12035-017-0632-1
  57. Miller A.H., Raison C.L. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016; 16 (1): 22–34. DOI: 10.1038/nri.2015.5
  58. Lichtman J.H., Froelicher E.S., Blumenthal J.A., Carney R.M., Doering L.V., Frasure-Smith N., Wulsin L. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: Systematic review and recommendations. Circulation. 2014; 129(12): 1350–1369. DOI: 10.1161/CIR.0000000000000019
****
  1. Trybhat T.A., Shut S.V., Borisova Z.O., Sakevych V.D., Goncharova O.O. Some characteristics of the course of coronary heart disease with a comorbid pathology. Med. Ecol. Probl. 2020; 24 (1–2): 8–11. DOI: 10.31718/mep.2020.24.1-2.02
  2. Golukhova E.Z. Report on the scientific and clinical activity of Bakoulev National Medical Research Center for Cardiovascular Surgery for 2023 and development prospects. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2024; 25 (Special Issue): 5–141 (in Russ). DOI: 10.24022/1810-0694-2024-25S
  3. Zheng W., Huang X., Wang X., Suo M., Yan Y., Gong W., Nie S. Impact of multimorbidity patterns on outcomes and treatment in patients with coronary artery disease. Eur. Heart J. Open. 2024; 4 (2): 1–8. DOI: 10.1093/ehjopen/oeae009
  4. Buziashvili Yu.I., Asymbekova E.U., Tugeeva E.F., Akhmedov D.R., Akildzhonov F.R. Multimodal approach to early verification of chemotherapy-associated cardiotoxicity. The Bulletin of Bakoulev Center. Cardiovascular Diseases. 2025; 26 (1): 5–12 (in Russ.). DOI: 10.24022/1810-0694-2025-26-1-5-12
  5. Forman D.E., Maurer M.S., Boyd C., Brindis R., Salive M.E., Horne F.M., Rich M.W. Multimorbidity in older adults with cardiovascular disease. J. Am. Coll. Cardiol. 2018; 71 (19): 2149–2161. DOI: 10.1016/j.jacc.2018.03.022
  6. Mamalyga M.L. Contemporary problems of cardiovascular disorders at diabetes mellitus. Int. J. Diabetes Endocrinol. 2016; 1 (1): 1–7. DOI: 10.11648/j.ijde.20160101.11
  7. Guzik T.J., Touyz R.M. Oxidative stress, inflammation, and vascular aging in hypertension. Hypertension. 2017; 70 (4): 660–667. DOI: 10.1161/HYPERTENSIONAHA.117.07802
  8. Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J., Ziaeian B. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J. Am. Coll. Cardiol. 2019; 74 (10): e177–e232. DOI: 10.1016/j.jacc.2019.03.010
  9. Low Wang C.C., Hess C.N., Hiatt W.R., Goldfine A.B. Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation. 2021; 133 (24): 2459–2502. DOI: 10.1161/CIRCULATIONAHA.116.022194
  10. Libby P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 2006; 83 (2): 456S–460S. DOI: 10.1093/ajcn/83.2.456S
  11. Jia G., Hill M.A., Sowers J.R. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ. Res. 2018; 122 (4): 624–638. DOI: 10.1161/CIRCRESAHA.117.311586
  12. Ginsberg H.N., Packard C.J., Chapman M.J., Borén J., Aguilar-Salinas C.A., Averna M., Tokgözoğlu L. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies – a consensus statement from the European Atherosclerosis Society. Eur. Heart J. 2021; 42 (47): 4791–4806. DOI: 10.1093/eurheartj/ehab551
  13. Libby P., Ridker P.M., Hansson G.K. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011; 473 (7347): 317–325. DOI: 10.1038/nature10146
  14. Tousoulis D., Oikonomou E., Economou E.K., Crea F., Kaski J.C. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur. Heart J. 2016; 37 (22): 1723–1732. DOI: 10.1093/eurheartj/ehv759
  15. Mamalyga M.L. Diabetes mellitus and its role in the formation of cardiovascular diseases. M.: Prometej; 2016 (in Russ.).
  16. Seferović P.M., Petrie M.C., Filippatos G.S., Anker S.D., Rosano G., Bauersachs J., Coats A.J. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology. Eur. J. Heart Fail. 2018; 20(5): 853–872. DOI: 10.1002/ejhf.1170
  17. Sarnak M.J., Amann K., Bangalore S., Cavalcante J.L., Charytan D.M., Craig J.C. Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. J. Am. Coll. Cardiol. 2019; 74 (14): 1823–1838. DOI: 10.1016/j.jacc.2019.08.1017
  18. Lanzer P., Boehm M., Sorribas V., Thiriet M., Janzen J., Zeller T. Medial vascular calcification revisited: review and perspectives. Eur. Heart J. 2014; 35 (23): 1515–1525. DOI: 10.1093/eurheartj/ehu163
  19. Mullens W., Cotter G., Metra M., Milo-Cotter O., Dittrich H.C., Gheorghiade M. Fluid overload in acute heart failure – re-distribution and other mechanisms beyond fluid accumulation. Eur. J. Heart Fail. 2008; 10 (2): 165–169. DOI: 10.1016/j.ejheart.2008.01.007
  20. Xie X., Liu Y., Perkovic V., Li X., Ninomiya T., Hou W., Wang H. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am. J. Kidney Dis. 2016; 67 (5): 728–741. DOI: 10.1053/j.ajkd.2015.10.011
  21. Tanaka H., Komaba H., Koizumi M., Kakuta T., Fukagawa M. Role of uremic toxins and oxidative s tress in the development of chronic kidney disease–mineral and bone disorder. J. Ren. Nutr. 2012; 22 (1): 98–101. DOI: 10.1053/j.jrn.2011.10.031
  22. Rangaswami J., Bhalla V., Blair J.E., Chang T.I., Costa S., Lentine K.L. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2019; 139 (16): 840–878. DOI: 10.1161/CIR.0000000000000664
  23. Portolés J., Martín L., Broseta J.J., Cases A. Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents. Front. Med. 2021; 8: 642296. DOI: 10.3389/fmed.2021.642296
  24. Kent B.D., Mitchell P.D., McNicholas W.T. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int. J. Chron. Obstruct. Pulmon. Dis. 2011; 6: 199–208. DOI: 10.2147/COPD.S10611
  25. Tariq S., Ismail D., Thapa M., Goriparthi L., Pradeep R., Khalid K., Jean-Charles G. Chronic obstructive pulmonary disease and its effect on red blood cell indices. Cureus. 2023; 15 (3): e36100. DOI: 10.7759/cureus.36100
  26. Seeger W., Adir Y., Barberà J.A., Champion H., Coghlan J.G., Cottin V., Vachiery J.L. Pulmonary hypertension in chronic lung diseases. J. Am. Coll. Cardiol. 2013; 62 (25): 109–116. DOI: 10.1016/j.jacc.2013.10.036
  27. Campo G., Pavasini R., Malagù M., Mascetti S., Biscaglia S., Ceconi C., Contoli M. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc. Drugs Ther. 2015; 29: 147–157. DOI: 10.1007/s10557-015-6581-x
  28. Roversi S., Roversi P., Spadafora G., Rossi R., Fabbri L.M. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur. J. Clin. Invest. 2014; 44 (1): 93–102. DOI: 10.1111/eci.12181
  29. Ortega-Paz L., Capodanno D., Angiolillo D.J. Canakinumab for secondary prevention of coronary artery disease. Future Cardiol. 2021; 17 (3): 427–442. DOI: 10.2217/fca-2020-0211
  30. Miklós Z., Horváth I. The role of oxidative stress and antioxidants in cardiovascular comorbidities in COPD. Antioxidants. 2023; 12(6): 1196. DOI: 10.3390/antiox12061196
  31. Daher A., Dreher M. The bidirectional relationship between chronic obstructive pulmonary disease and coronary artery disease. Herz. 2020; 45 (2): 110–117. DOI: 10.1007/s00059-020-04893-4
  32. Brown T.M., Pack Q.R., Aberegg E., Brewer L.C., Ford Y.R., Forman D.E., Thomas R.J. Core components of cardiac rehabilitation programs: 2024 update: a scientific statement from the American Heart Association and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation. 2024; 150 (18): 328–347. DOI: 10.1161/CIR.0000000000001289
  33. Evdokimov V., Yushchuk E., Evdokimova A., Ivanova S., Sadulaeva I. Efficacy and safety of beta-blockers and prolonged bronchodilators in patients with heart failure with coronary artery disease and moderate to severe COPD. Eur. Heart J. 2020; 41 (2): 946–1156. DOI: 10.1093/ehjci/ehaa946.1156
  34. Jabbar A., Pingitore A., Pearce S.H., Zaman A., Iervasi G., Razvi S. Thyroid hormones and cardiovascular disease. Nat. Rev. Cardiol. 2017; 14 (1): 39–55. DOI: 10.1038/nrcardio.2016.174
  35. Gluvic Z.M., Zafirovic S.S., Obradovic M.M., Sudar-Milovanovic E.M., Rizzo M., Isenovic E.R. Hypothyroidism and risk of cardiovascular disease. Curr. Pharm. Des. 2022; 28 (25): 2065–2072. DOI: 10.2174/1381612828666220620160516
  36. Klein I., Ojamaa K. Thyroid hormone and the cardiovascular system. N. Engl. J. Med. 2001; 344 (7): 501–509. DOI: 10.1056/NEJM200102153440707
  37. Ochs N., Auer R., Bauer D.C., Nanchen D., Gussekloo J., Cornuz J., Rodondi N. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann. Intern. Med. 2008; 148 (11): 832–845. DOI: 10.7326/0003-4819-148-11- 200806030-0022
  38. Udovcic M., Pena R.H., Patham B., Tabatabai L., Kansara A. Hypothyroidism and the heart. Methodist. DeBakey Cardiovasc. J. 2017; 13 (2): 55–59. DOI: 10.14797/mdcj-13-2-55
  39. Bano A., Chaker L., De Maat M.P., Atiq F., Kavousi M., Franco O.H., Peeters R.P. Thyroid function and cardiovascular disease: the mediating role of coagulation factors. J. Clin. Endocrinol. Metab. 2019; 104 (8): 3203–3212. DOI: 10.1210/jc.2019-00072
  40. Jean-Louis G., Zizi F., Clark L.T., Brown C.D., McFarlane S.I. Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J. Clin. Sleep Med. 2008; 4 (3): 261–272. DOI: 10.5664/jcsm.27191
  41. Mooe T., Franklin K.A., Holmstrom K., Rabben T., Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am. J. Respir. Crit. Care Med. 2001; 164 (10): 1910–1913. DOI: 10.1164/rccm.2101072
  42. May A.M., Mehra R. Obstructive sleep apnea: role of intermittent hypoxia and inflammation. Semin. Respir. Crit. Care Med. 2014; 35 (5): 531–544. DOI: 10.1055/s-0034-1390023
  43. Jelic S., Lederer D.J., Adams T., Padeletti M., Colombo P.C., Factor P., Le Jemtel T.H. Endothelial repair capacity and apoptosis are inversely related in obstructive sleep apnea. Vasc. Health Risk Manag. 2009; 5: 909–920. DOI: 10.2147/VHRM.S8123
  44. Punjabi N.M., Sorkin J.D., Katzel L.I., Goldberg A.P., Schwartz A.R., Smith P.L. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am. J. Respir. Crit. Care Med. 2002; 165 (5): 677–682. DOI: 10.1164/rccm.2104087
  45. Golukhova E.Z., Magomedova N.M. Obstructive sleep apnea and the risk of cardiovascular disease. Creative Cardiology. 2016; 10(3): 201–209 (in Russ.) DOI: 10.15275/kreatkard.2016.03.03
  46. Guardiola J.J., Matheson P.J., Clavijo L.C., Wilson M.A., Fletcher E.C. Hypercoagulability in patients with obstructive sleep apnea. Sleep Med. 2001; 2 (6): 517–523. DOI: 10.1016/S1389-9457(01)00088-0
  47. Johansson P., Alehagen U., Ulander M., Svanborg E., Dahlström U., Broström A. Sleep disordered breathing in community dwelling elderly: associations with cardiovascular disease, impaired systolic function, and mortality after a six-year follow-up. Sleep Med. 2011; 12 (8): 748–753. DOI: 10.1016/j.sleep.2011.03.012
  48. Somers V.K., Amin R., Abraham W.T., Costa F., Culebras A., Young T. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement. J. Am. Coll. Cardiol. 2008; 52 (8): 686–717. DOI: 10.1016/j.jacc.2008.05.002
  49. Celano C.M., Villegas A.C., Albanese A.M., Gaggin H.K., Huffman J.C. Depression and anxiety in heart failure: a review. Harv. Rev. Psychiatry. 2018; 26 (4): 175–184. DOI: 10.1097/HRP.0000000000000162
  50. Otte C., Gold S.M., Penninx B.W., Pariante C.M., Etkin A., Fava M., Schatzberg A.F. Major depressive disorder. Nat. Rev. Dis. Primers. 2016; 2: 16065. DOI: 10.1038/nrdp.2016.65
  51. Xu L., Zhai X., Shi D., Zhang Y. Depression and coronary heart disease: mechanisms, interventions, and treatments. Front. Psychiatry. 2024; 15: 1328048. DOI: 10.3389/fpsyt.2024.1328048
  52. Pariante C.M. Why are depressed patients inflamed? A reflection on 20 years of research on depression, glucocorticoid resistance and inflammation. Eur. Neuropsychopharmacol. 2017; 27 (6): 554–559. DOI: 10.1016/j.euroneuro.2017.04.001
  53. Jesulola E., Micalos P., Baguley I.J. Understanding the pathophysiology of depression: From monoamines to the neurogenesis hypothesis model-are we there yet? Behav. Brain Res. 2018; 341: 79–90. DOI: 10.1016/j.bbr.2017.12.025
  54. Golukhova E.Z., Aslanidis I.P., Shurupova I.V., Shakhova A.A., Rumyantseva M.G., Trifonova T.A., Surkova N.A. Regional myocardial perfusion abnormalities and reducing myocardial blood flow values in predicting multivessel coronary artery disease. Grudnaya i Serdechno-Sosudistaya Khirurgiya. 2023; 65 (2): 161–172 (in Russ.). DOI: 10.24022/ 0236-2791-2023-65-2-161-172
  55. Golukhova E.Z., Shurupova I.V., Dorofeev A.V., Rychina I.E., Trifonova T.A., Boldyreva K.M. Characteristics of global myocardial blood flow and coronary reserve according to dynamic computed stress tomography in patients with coronary artery disease. Grudnaya I Serdechno-Sosudistaya Khirurgiya. 2024; 66 (5): 655–667 (in Russ.). DOI: 10.24022/0236-2791-2024-66-5-655-667
  56. Köhler C.A., Freitas T.H., Stubbs B., Maes M., Solmi M., Veronese N., Carvalho A.F. Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: Systematic review and meta-analysis. Mol. Neurobiol. 2018; 55 (5): 4195–4206. DOI: 10.1007/s12035-017-0632-1
  57. Miller A.H., Raison C.L. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016; 16 (1): 22–34. DOI: 10.1038/nri.2015.5
  58. Lichtman J.H., Froelicher E.S., Blumenthal J.A., Carney R.M., Doering L.V., Frasure-Smith N., Wulsin L. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: Systematic review and recommendations. Circulation. 2014; 129(12): 1350–1369. DOI: 10.1161/CIR.0000000000000019

About Authors

  • Sergey G. Kanorsky, Dr. Med. Sci., Professor, Head of the Department of Therapy No 2; ORCID
  • Lily V. Polischuk, Cand. Med. Sci., Assistant; ORCID
  • Vladimir V. Pokrovsky, Dr. Med. Sci., Professor; ORCID

 If you found mistakes, select text and press Alt+A